Lei Gong



Lei Gong has over 20 years’ Investment Banking experience. He was most recently the Managing Director and China Healthcare Head of BDA Partners. Previously, he acted as the Managing Director and China M&A head and was the Investment Banking Committee (China) member of Daiwa Securities for 7 years, where he was responsible for origination and execution of cross-border M&A and covering Chinese blue-chip clients. He has rich sector knowledge and deep relationship with global funds in the Chinese market.

He worked with many leading companies across various industries, including advising MicroPort Medical in its acquisition of Germany’s ECMO Hemovent, Chalkis health’s acquisition of French Le-cabanon, restructuring of Shanghai SVA group, China TianYin’s acquisition of Spanish Urbaser and advising Kobayashi Pharma partners in its JV with Sino Pharma.

He holds a Master degree in Finance from the Shanghai University of Finance and Economics.

Scroll to Top